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Abstract
Background: Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In
recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.)
or intravenous (i.v.) application. The aim of this innovative trial was to evaluate the preference of elderly patients
(≥65 years) for p.o. or i.v. chemotherapy focusing compliance, outcome, toxicities, and geriatric aspects as
secondary endpoints.
Methods: Patients with ROC had the free choice between treosulfan i.v. (7000 mg/m2 d1, q29d) or p.o. (600 mg/m2
daily d1-28, q57d). Only indecisive participants were randomized.
Results: Overall 123 patients with 2nd to 5th recurrence were registered and 119 received at least one cycle of
chemotherapy. 85.7% preferred treosulfan i.v. and 14.3% oral, where only three patients were randomized. Main
reasons for i.v. preference associated with individual expectations of lower rate of gastrointestinal disorders, higher
activity and tolerability of treatment. Median of applied chemotherapies was three (range 1–12 cycles), with most
common grade 3/4 toxicities thrombopenia (18.7%), leukopenia (15.7%), ascites (7.6%), bowel obstruction (6.7%),
and abdominal pain (4.2%). Median time until progression/overall survival was 5.2/7.8 months (i.v.), and 5.6/10.
4 months (p.o.), respectively, without significant differences in efficacy.
Conclusions: Elderly patients with recurrent ovarian cancer asked and demonstrated active participation in the
decision-making process of their oncological treatment and favoured predominantly the i.v. application. Treosulfan
was generally well-tolerated despite comorbidities and heavy pre-treatment. Our study demonstrates that patients’
preference did not influence prognosis negatively and remains important in gynaecologic oncology decision
practice.
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Background
Treatment of elderly ovarian cancer patients remain a great
challenge in the palliative situation, where innovative ther-
apies conflicts with clinical routine [1–3]. In general some
physicians consider critical surgical or systemic treatment
[4, 5] while many observers reported inadequate treatment
quality in elderly compared to younger patients [3, 6–8].
Otherwise age was one of the common exclusion criteria in
clinical trials, so their results could not consequently be
transferred to senior cancer cohorts. Additional, age-
dependent limitations of functional reserves are not well
understood, but complex and require elaborate assessment
[9, 10]. In particular, individual preferences and knowledge
of patient reported outcome measures are key aspects of
palliative concepts [11]. Resent published data have con-
firmed opposing expectations and individual preferences by
cancer patients and their physicians [11–13]. Today data
focusing elderly ovarian cancer patients, their prefer-
ences and expectations for therapy are still limited,
thus to change the primary perspective in a clinical
trial is provoking but could generate a helpful insight
to gynaecologic oncologists.
As factors of decision-making in oncology are poorly
understood, there is an ongoing intensive discussion
about new conceptual and scientific approaches [14].
Not only efficacy and toxicity, but also patient’s accept-
ance of and compliance with treatment can significantly
influence outcome [1, 3]. Inadequate therapy of elderly
results quite often due to the erroneous belief that age
alone determines lower tolerability to surgery and
chemotherapy [15]. There is also controversial experi-
ence that, even in a palliation, elderly women can pos-
sibly tolerate debulking surgery and chemotherapy well,
but still prediction of the individual aspects, benefits and
risk is still not possible [8, 16]. Thus optimising strat-
egies for increasing compliance and satisfaction with
care should involve patients into the treatment decision-
making process, above all respecting their expectations
and preferences [13, 17, 18].
Treosulfan is a bifunctional alkylating prodrug show-
ing activity for the i.v. formulation either as a single
agent or in combination with other cytotoxic drugs such
a cisplatin [19–21]. Furthermore, oral treosulfan demon-
strated a high and constant bioavailability [22], which
may lead to the same efficacy. Since both formulations
show a similar efficacy and moderate toxicity, it seems
attractive for evaluating individual therapy preferences.
Treosulfan is approved in several European countries for
the treatment of ovarian cancer and characterized by
proven effectivity and mild toxicity (e.g. little hair loss
and non-haematological side-effects), which makes it at-
tractive for geriatric and multimorbid patients [23].
The innovative concept of this trial involved elderly pa-
tients with recurrent ovarian cancer to determine active
their preference for therapy after detailed patient consult-
ation on treatment aims and risks. Primary study objec-
tives were the individual preference and free patient’s
choice to chemotherapy with either i.v. or p.o. treosulfan.
Additionally, we evaluated the reasons for individual
choice and analysed compliance, tolerability, and efficacy
of the different application routes. Patients were free to
participate on geriatric assessment measures.
Methods
Study design
This was an open-label, multicentre trial of treosulfan in
elderly women with ROC. Patients were enrolled into
the study after failure of platinum-containing treatment,
irrespective of their treatment-free interval, following an
innovative registration design: they were free to choose
between oral and i.v. treosulfan treatment. Only indeci-
sive participants were randomized.
Patients were enrolled at 27 German institutions
(18 hospitals, nine outpatient facilities). Women ≥
65 years with recurrent ovarian, peritoneal, or fallopian
tube cancer were eligible. Key inclusion criteria were as fol-
lows (selection): ECOG ≤ 2, serum creatinine ≤ 1.25 × upper
normal limit (UNL), bilirubin ≤ 1.25 × UNL (in the pres-
ence of liver metastases ≤ 5 × UNL), and adequate bone
marrow function (leucocytes ≥ 2.0 · × 109/l, and platelet
count ≥ 100 × 109/l). Initially, only patients in the second
line situation (first recurrence) were allowed to participate,
but due to emerging trial results and improvement of
national guidelines for the treatment of ovarian cancer, the
subsequent change of inclusion criteria to patients with at
least two previous therapies (≥3rd line situation) was
amended.
The primary aim was to explore the preference and
compliance of elderly participants for the palliative treat-
ment with oral or i.v. medication. Secondary objectives in-
cluded compliance, toxicity, progression-free and overall
survival. Additional quality of life, functional and comor-
bidity measures and geriatric assessments were performed
according to the preference of the participants.
This trial was planned by the North-Eastern German
Society of Gynaecological Oncology (NOGGO) Ovarian
Cancer Study Group. The study was performed according
to ICH-GCP (International Conference on Harmonization
- Good Clinical Practice) guidelines after obtaining central
ethical committee’s approval and trial registration
(EudraCT Nr.: 2004-000719-25; NCT 00170690). Written
informed consent was provided by each participant.
Treatment plan and toxicity evaluation
Patients received a standard dose of 7000 mg/m2 treo-
sulfan i.v. on day 1 of a 28-day cycle or 600 mg/m2 p.o.
on days 1–28 of a 56-day cycle for a maximum of
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12 months or until disease-progression or development
of unacceptable toxicity.
The screening started within 14 days prior to start of
therapy included an evaluation of the medical history, a
physical examination, and a tumour evaluation, staged by
CA 125 and radiological imaging (chest x-ray, ultrasound,
CT or MRI scan). Laboratory analyses comprised haema-
tology (biweekly), serum chemistry, and urine analysis.
Evaluation of response was performed every 12 weeks or
in case of symptoms or signs of tumour progression.
Toxicity was classified according to the NCI- CTCAE
version 2.0. Safety analyses were performed on all pa-
tients who received at least one therapy cycle. In order
to account for the limited haematopoietic resources of
elderly patients, chemotherapy was applied only if
leukocyte was ≥ 3.5 × 109/l and platelets ≥ 100× 109/l.
In cases of dose reduction due to severe haematological
toxicity, no re-escalation was allowed. Tumour progres-
sion, intolerable toxicity (grade 3/4), and/or a treatment
delay > 2 weeks led to discontinuation of treatment.
Statistical analysis
The preference for oral or i.v. treosulfan was expected to
result in a variable compliance. Description of compli-
ance differences between the two treatment arms by
15% was defined as clinically significant. We used Fleiss
statistical measurement to optimize the sample size [24].
Setting the test criteria to alpha = 5%, beta = 20% and a
drop-out rate of 5%, 160 patients were initially intended
to be recruited for this trial. Due to a slow recruitment
we performed a prior evaluation with 123 patients iden-
tifying highly representative differences in preference
and compliance, which were statistically significant to
close early trial recruitment.
Results are presented as proportions, means, medians,
and rates, and their adequate measures of distribution.
We used a one-sample test of proportions to address the
primary hypothesis. All other endpoints were evaluated
in an exploratory fashion, and 95% confidence intervals
(CI) were computed where appropriate.
Evaluation of response was performed by CA 125
monthly and by radiological assessment every 3 months.
Response was measured according to UICC-criteria and
CA-125 assessment criteria, established by Rustin et al.
[25]. Progression-free survival and overall survival were de-
fined as the interval between the first day of the study drug
application and disease progression or death due to any
cause. Both were calculated by the Kaplan-Meier method.
Results
Patient characteristics
Out of 123 registered patients, 119 received at least one
cycle of chemotherapy and were eligible for the final
analysis (Fig. 1). Generally, there were no significant
differences in the global patient characteristics (Table 1).
The median age at recruitment was 71 years (range of
65–87 years). Most women were diagnosed with ad-
vanced stage III/IV high-grade carcinomas of serous-
papillary histology and were in good condition (ECOG
0–1). The majority had received three previous cytotoxic
treatments (three in the i.v. and two in the oral prefer-
ence arm). Most patients were treated in this study due
to second or third recurrence (56.3%), but 32% had four
or more recurrences in their medical history. Because
the protocol allowed to register patients independently
of their platinum-free interval, the rate of late recur-
rences with a treatment-free interval >12 months was
between 35 and 52% (oral vs. i.v. group). Distant metas-
tases were rare and typically localized to the liver or
lung. The median number of concomitant diseases was
5 (range 1–9), mostly of cardiovascular, musculoskeletal
or gastrointestinal character (Table 2).
Preference for chemotherapy
During the registration process patients were asked to
realize their preference or to be randomized to treat-
ment. Most them (n = 116, 97.5%) preferred to choose
the application form of chemotherapy, thus only 3 in-
decisive women were randomized. A total of 85.7% or
102 patients realized their free choice to receive chemo-
therapy as i.v. application, where three were randomized
to this arm. Seventeen patients (14.3%) preferred the
oral therapy (no randomization to oral therapy). The
main reasons for individual preference to i.v. or p.o.
treosulfan are listed in Table 2.
Toxicity profile
In both treatment arms, most non-haematological and
haematological toxicities were of grade 1 or 2. The most
common grade 3/4 haematological side-effects were
thrombocytopenia, leukopenia, and neutropenia. Severe
non-haematological events were rare. Moreover, a re-
markably low rate of alopecia was observed (13.7% with
grade 1/2, no grade 3). No therapy-related death was ob-
served (Table 3).
Treatment delay and discontinuation
In total, 421 cycles of treosulfan (median 3, range 1–12)
were administered. Dose reductions were performed in
27 courses of treosulfan therapy (6.4%, 1 oral and 26 i.v.
arm, see Table 3), whereas for 96 courses (22.8%), an
interval prolongation was necessary. The main reason
for dose reduction were haematological AEs and for
treatment delay haematological toxicity and organisa-
tional reasons/preference.
Six Patients (35.3%) preferring oral application re-
ceived three courses of therapy, but only three patients
(17.6%) finished all planned 6 cycles (12 months). In the
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i.v. group, 26 patients (25.4%) received six courses, but
only one received the maximum of 12 chemotherapies.
Disease progression and patient’s choice were main rea-
sons for discontinuing treatment. Subsequently 11.8% of
the i.v. participants discontinued therapy due to haem-
atological toxicities, whereas non-haematological events
were twice as high in the oral group (Table 3).
Response, survival, and follow-up
Seventy-four patients (65 i.v./ 9 p.o.) were considered as-
sessable for radiological response. One patient showed
complete response (1/0), 13 (11/2) partial remission
(PR), 15 (14/1) stable disease (SD), 45 (39/6) progressive
disease (PD), and 45 were not assessable for response
(lost of follow-up). During the study follow-up period,
105 patients (88.2%) died, mostly documented to disease
progress.
Median follow-up was 11.4 months. Median
progression-free survival in this study was 3.7 months (i.v.
3.5 months/p.o. 4.2 months). Median overall survival was
8.0 months, with 7.8 months (i.v.) and 10.4 months (p.o.),
respectively (Fig. 2). There was no statistically significant
difference between the two arms regarding survival.
Geriatric aspects
The highest participation in the geriatric assessment
with ADL and iADL questionnaires was achieved at the
start of therapy (70%), but declined during the study
period to less than 10%. Interestingly the proportion of
patients which declared to need support or help in their
activities of daily living (ADL) was significantly higher
within the individuals with preference for oral treatment,
but this effect was not demonstrated for the iADL-score.
Geriatric measurements did not demonstrate specific
differences in the patient preference profiles (Fig. 2).
Discussion
The key objectives in the treatment of recurrent ovarian
cancer (ROC) are preventing disease-related symptoms,
prolonging progression-free survival, and maintaining
quality of life [2, 26]. However, as more patients achieve
long-term survival, palliative care has evolved to include
all aspects of cancer survivorship, which increase the
Fig. 1 CONSORT diagram of trial profile
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need of new and thoroughly considered approaches fo-
cusing individual expectations, preference and accept-
ance of treatment [13, 27, 28]. Demographic switch
increase the expectations on clinicians and health care
providers, since multimodal management and identifica-
tion of subgroups with specific tumour characteristics is
gaining key importance [3, 29]. In this prospective study,
we evaluated the new strategy giving elderly patients the
opportunity to choose free the application route of their
chemotherapy and analysed prospectively their prefer-
ences. The great majority of 97% realized their preference,
demonstrating clearly high motivation to participate to
the decision making process. Unexpectedly most patients
preferred the i.v. application of the drug, associating oral
intake over long period with expected higher gastrointes-
tinal risks for reflux, hyperacidemia, nausea, change of
taste, loss of appetite or diarrhoea.
The monthly i.v. infusion seemed for many to be more
comfortable, since regular hospital and physician con-
tacts does not negatively influence patient’s autonomy
and compliance, as described by others [5, 18]. These
findings are remarkable, as physicians tend often to in-
consequent management of geriatric patients [3, 5, 26].
Multiple analyses demonstrated in the past, that elderly
were treated suboptimal, commonly under-represented
in clinical trials, which resulted in their unfavourable
outcome [3, 7]. Although data do not support the sug-
gestion that age – independently of any other factors –
is a negative prognostic factor, we need new clinical in-
struments to evaluate additionally aspects of acceptance,
preference and satisfaction with care, as well as social
and psychological scopes of treatment [1, 5]. Our trial
offers here unique aspects and insights to traditional
management and can help for more individualisation of
palliative ovarian cancer care.
Patient’s preference is known to be complex, to base on
individual experiences and reflecting on relevant life
events and be difficult to assess [30, 31]. Acceptance of
and compliance with oncological therapy plays a key role
for improving efficacy and prolonging survival. Age is the
strongest demographic factor affecting patients’ prefer-
ences: younger and better-educated patients, and women
Table 1 Patients’ characteristics and distribution of clinical
parameters according to individual preference, n = 119
Parameter of disease (n, %) Preference to treatment
i.v. (n = 102) oral (n = 17)
Median age, in years (range) 72 (65–87) 70 (65–77)
ECOG
0 22 (21.6) 4 (23.5)
1 68 (66.7) 10 (58.8)
2 12 (11.7) 3 (17.7)
FIGO stage at primary diagnosis
I 2 (2) 1 (5.9)
II 7 (6.9) 1 (5.9)
III 62 (60.8) 13 (76.5)
IV 25 (24.5) 2 (11.7)
not documented 6 (5.9) -
Histology
Serous papillary 59 (57.8) 13 (76.5)
Mucinous 12 (11.7) 3 (17.7)
Endometrioid 8 (7.8) 1 (5.9)
Others or NOS 23 (22.6) -
Grading at primary diagnosis
G1 2 (2) -
G2 29 (28.4) 5 (29.4)
G3 61 (59.8) 12 (70.6)
not documented 10 (9.8) -
Type of treatment in the adjuvant
situation or last recurrence
Surgical tumordebulking 100 (98) 17 (100)
Chemotherapy 101 (99) 17 (100)
Previous hormonal treatment 8 (7.8) 2 (11.8)
Previous Radiotherapy 6 (5.9) 1 (5.9)
Relapse-free interval after primary
platinum based therapy
< 6 months 21 (20.6) 4 (23.5)
6–12 months 28 (27.5) 7 (41.2)
> 12 months 53 (51.9) 6 (35.3)
Type of previous chemotherapy
regimens (n = 372)
platinum/taxan based 182 (56.9) 22 (44.9)
anthracyclin 38 (11.9) 6 (12.2)
topotecan 45 (14) 9 (18.4)
taxan 12 (3.8) 1 (2.1)
others 43 (13.4) 11 (22.4)
No. of previous chemotherapies
for all median (min. / max.)
3 (1–8)
3 (1–8) 2 (1–7)
Table 1 Patients’ characteristics and distribution of clinical
parameters according to individual preference, n = 119
(Continued)
Recurrent situation at time of
registration
1. Recurrence 13 (12.7) 1 (5.9)
2. Recurrence 25 (24.5) 8 (47)
3. Recurrence 30 (29.4) 4 (23.5)
4. Recurrence 15 (14.7) 2 (11.8)
> 4 Recurrencies 19 (18.6) 2 (11.8)
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in general, were reported to prefer more active role in
decision-making [31]. Degner et al. identified a large vari-
ation in preferred and attained levels of involvement in
the treatment decisions for breast cancer patients [32].
Our analysis identified that, even after extensive pre-
treatment (median of 3 previous therapies) and in highly
palliative situation elderly ovarian cancer patients prefer
to realize their individual preference and accept the corre-
sponding treatment. Therapy discontinuation remained
low, mostly due to tumour progression or toxicity. The i.v.
regimen seems to demonstrate a partly favourable toxicity
compared to oral treosulfan. Interestingly, this corresponds
Table 2 Reasons for treatment preference and concomitant
diseases (n = 119)
Characteristics i.v., n = 102,
(%)
Oral, n = 17,
(%)




Main reasons for therapy
preference
Wish to avoid gastrointestinal
disorders
20 (19.6) 0
Disfavour / poor toleration of
oral drugs
12 (17.8) 0
Oblivion / daily oral intake is
unsure
14 (13.7) 0
Believe i.v. application is saver
over i.v. port
15 (14.7) 0
More effective / higher
treatment pressure
13 (12.3) 1 (5.9)
Oral drug application not
possible - short bowel/subileus
4 (3.9) 0
Pre-existing chronic diarrhoea /
vomiting
4 (3.9) 0
Expect better tolerability 4 (3.9) 0
Wish no hospital treatment /
more independence / privacy
0 6 (35.3)
The handling of the therapy
is simple
0 4 (23.5)
Continuity of the drug
administration / maintenance effect
0 2 (11.8)
Made bad experience with venous
puncture
0 1 (5.9)
Reason for preference not
documented
16 (17.6) 3 (17.7)
Concomitant diseases
(multiple answers)
Cardiovascular 92 (90.2) 17 (100)
Musculoskeletal 37 (36.3) 7 (41.2)
Pulmonary 28 (27.5) 2 (11.8)
Lower gastrointestinal tract 39 (38.2) 4 (23.5)
Upper gastrointestinal tract 27 (26.5) 4 (23.5)
Metabolic and hormonal 25 (24.5) 6 (35.3)
Hepatic 27 (26.5) 3 (17.7)
Renal 12 (11.8) 6 (35.3)
Urinary tract 21 (20.6) 2 (11.8)
Neurological 27 (26.5) 7 (41.2)
Psychiatric 6 (5.9) 4 (23.5)
Table 3 Toxicity, dose reduction and reasons for therapy
discontinuation (n = 119)
Parameter i.v., n = 102
(%)
Oral, n = 17
(%)






Febrile Neutropenia 7 -
Non-haematological (all grade)
Ascites 9.9 11
Subileus (severe constipation) 8.6 11
Constipation 6.2 -
Abdominal pain 4.9 11




Rectal incontinence 2.5 -
Others (< 1%) 51.8 56
Dose reduction (27 of all 421 cycles) 6.4
(26 of 376 i.v. cycles vs. 1 of 45 oral
cycles)
6.9 2.2
Prolongation of treatment interval
(> 14d)
25 4.4
Reasons for early therapy
discontinuation
Progressive disease 42 47.1
Patients preference 15.7 11.8
Other reasons 15.7 11.8
Haematological toxicity (grade 3/4) 11.8 -




Concomitant disease 2.9 5.9
Complete remission 1 -
Main cause of death
Tumour related 80.4 82.4
Others 7.8 5.9
aadverse events
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with the patients’ expectation of a milder effect on the
gastrointestinal tract, which, in turn, was declared to guar-
antee more safety. On the other hand, patients expected a
better control over their treatment since the application
takes place in a hospital/outpatient department and
associated the corresponding influence with expected posi-
tively affection on their outcome. This reflects report of
close relationship of oncological patients to their treating
physicians and palliative care teams as one of their most
important representatives during the treatment [11, 13, 28].
Fig. 2 Distribution of severe geriatric assessment inside patients with i.v. and oral preference. ADL = activities of daily living; iADL = instrumental
activities of daily living
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Otherwise the possibility of realizing one’s own preference
evidently has the strongest psychological impact [33].
Despite all limitations of the small patient cohort and
the non-mandatory evaluation of geriatric measures, this
trial report interesting insight into a very complex pallia-
tive cohort of geriatric patients. Although the observed
disease stabilisation was mostly brief, only a small number
of participants interrupted their study participation at their
own request, keeping their compliance and acceptance
high. Despite methodical limitations due to the imbalance
of patient distribution, our results are comparable with data
by Pfeiffer et al, who reported preference for i.v. chemother-
apy within colon cancer outpatients, probably due to ex-
pected lower toxicity [18].. In contrast, other groups
reported preference for oral chemotherapy, within younger
breast cancer patients associated with their better func-
tional and physiological status, less comorbidities, and the
wish for more individuality in their daily activities [1, 13]..
A certain bias in the trial design consisted, perhaps, in the
fact that, in most cases, in these trials an established i.v.
drug was compared to an “innovative” oral formulation,
which seemed more attractive [17, 18, 32, 34].
The frequency of concomitant diseases registered in our
cohort was high, mostly of moderate severity, and, typic-
ally, resulted in more co-medication. It is well-known that
multimorbidity may influence patient decisions, favouring
tolerability while trying to balance risks and potential ben-
efits [6]. Recently published data has not reported signifi-
cant impact on early treatment discontinuation of
chemotherapy in cohort of 1213 patients with relapsed
ovarian cancer [35]. Although only some physical and
emotional domains of quality of life were described most
salient, there is no prospective evaluation in ovarian can-
cer patients and distinct domains are more than heteroge-
neous [36, 37]. Exemplarily patients after extensive
tumour debulking with gross bowel resection, who are not
able to resorb oral drugs due to consequently insufficient
bowel metabolism, needs quite different treatment strat-
egy as an elderly and frail patient with accumulated
gastrointestinal toxicity [35, 38]. Thus, knowledge of late
effects of cancer survivals and their individual preferences
could help to modify possible ineffective treatment and in-
crease satisfaction with care, but have to be studied sys-
tematic in a prospective approach [13, 38].
Summarising elderly ovarian cancer patients demon-
strated a high motivation to realize their treatment
preference, despite their comorbidity, co-medication and
previous chemotherapy experience. The preference for
i.v. chemotherapy in this palliative cohort could be de-
scribed with subjective expectations and individual expla-
nations to toxicity, safety and treatment potency which
are difficult to be quantified objective. As expected there
were no severe toxicities or differences in efficacy ob-
served [39, 40]. Thus the concept of a patient’s free choice
following preference for the drug application form could
be an attractive option in the treatment of ROC, especially
in elderly and comorbid patients with heavily pre-treated
recurrence.
Conclusions
Elderly patients with recurrent ovarian cancer have clear
preferences and are motivated to participate to the treat-
ment decision process. In the palliative situation they
preferred the i.v. application of treosulfan, based on indi-
vidual experience with toxicity, comorbidity and co-
medication, which reflects their specific geriatric
situation.
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